Alnylam announces u.s. food and drug administration (fda) acceptance of supplemental new drug application for onpattro® (patisiran) for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the u.s. food and drug administration (fda) has accepted for filing the company's supplemental new drug application (snda) for patisiran, an investigational rnai therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (attr) amyloidosis.
ALNY Ratings Summary
ALNY Quant Ranking